Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 2, 2008, Pages 134-138

  Hosohata, Keiko ^a   Masuda, Satohiro ^a   Ogura, Yasuhiro ^b   Oike, Fumitaka ^b   Takada, Yasutsugu ^b   Katsura, Toshiya ^a   Uemoto, Shinji ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

CYP2C19; CYP3A5; Lansoprazole; Living donor liver transplantation; Rabeprazole; Tacrolimus

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; GENOMIC DNA; LANSOPRAZOLE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; PREDNISOLONE; RABEPRAZOLE; TACROLIMUS; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; CYP2C19 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOLOGICAL ADJUVANT; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CASE REPORT; DIGESTIVE SYSTEM ULCER; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME DEFECT; EVENING DOSAGE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MALE; MORNING DOSAGE; PLASMA CONCENTRATION-TIME CURVE; POSTOPERATIVE CARE; DRUG INTERACTION; MIDDLE AGED; PHYSIOLOGY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADJUVANTS, IMMUNOLOGIC; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; TACROLIMUS;

EID: 43749101127     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.134     Document Type: Article

References (15)

1. Shiraga, T., Matsuda, H., Nagase, K., Iwasaki, K., Noda, K., Yamazaki, H., Shimada, T. and Funae, Y.: Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol., 47: 727-35 (1994).
2. Pearce, R. E., Rodrigues, A. D., Goldstein, J. A. and Parkinson, A.: Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther., 277: 805-16 (1996).
3. Yasuda, S., Horai, Y., Tomono, Y., Nakai, H., Yamato, C., Manabe, K., Kobayashi, K., Chiba, K. and Ishizaki. T.: Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to Smephenytoin 4′-hydroxylation status. Clin Pharmacol Ther., 58: 143-54 (1995).
4. De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K. and Goldstein, J. A.: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol., 46: 594-8 (1994).
5. van Schaik, R. H., van der Heiden, I. P., van den Anker, J. N. and Lindemans, J.: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem., 48: 1668-71 (2002).
6. Pauli-Magnus, C., Rekersbrink, S., Klotz, U. and Fromm, M. F.: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol., 364: 551-7 (2001).
7. Itagaki, F., Homma, M., Takara, K., Ohnishi, N., Yokoyama, T., Sakaeda, T., Yagami, T., Kobayashi, H., Okamura, N. and Kohda, Y.: Effect of rabeprazole on MDR1-mediated transport of Rhodamine 123 in Caco-2 and Hvr100-6 cells. Biol Pharm Bull., 27: 1694-6 (2004).
8. Hebert, M. F.: Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev., 7: 201-214 (1997).
9. Hashida, T., Masuda, S., Uemoto, S., Saito, H., Tanaka, K. and Inui, K.: Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther., 69: 308-316 (2001).
10. Masuda, S., Goto, M., Kiuchi, T., Uemoto, S., Kodawara, T., Saito, H., Tanaka, K. and Inui, K.: Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transpl., 9: 1108-1113 (2003).
11. Masuda, S., Goto, M., Okuda, M., Ogura, Y., Oike, F., Kiuchi, T., Tanaka, K. and Inui, K.: Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. Transplant Proc., 37: 1728-1729 (2005).
12. Masuda, S. and Inui, K.: An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther., 112: 184-198 (2006).
13. Itagaki, F., Homma, M., Yuzawa, K., Fukao, K. and Kohda, Y.: Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Transplant Proc., 34: 2777-8 (2002).
14. Takahashi, K., Motohashi, H., Yonezawa, A., Okuda, M., Ito, N., Yamamoto, S., Ogawa, O. and Inui, K.: Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother., 38: 791-4 (2004).
15. Uesugi, M,, Masuda, S., Katsura, T., Oike, F., Takada, Y. and Inui, K.: Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics., 16: 119-27 (2006).